Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PIK3CA E545K
i
Other names:
PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5290
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Related tests:
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (20)
therascreen® PIK3CA RGQ PCR Kit (3)
FoundationOne® CDx (110)
FoundationOne® Liquid CDx (20)
therascreen® PIK3CA RGQ PCR Kit (3)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PIK3CA E545K
Colorectal Cancer
PIK3CA E545K
Colorectal Cancer
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
cetuximab
Resistant: C3 – Early Trials
cetuximab
Resistant
:
C3
PIK3CA E545K
Non Small Cell Lung Cancer
PIK3CA E545K
Non Small Cell Lung Cancer
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
osimertinib
Resistant: C3 – Early Trials
osimertinib
Resistant
:
C3
PIK3CA E545K
Ovarian Cancer
PIK3CA E545K
Ovarian Cancer
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
TAS-117
Sensitive: C3 – Early Trials
TAS-117
Sensitive
:
C3
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
olaparib + durvalumab + capivasertib
Sensitive: C3 – Early Trials
olaparib + durvalumab + capivasertib
Sensitive
:
C3
olaparib + durvalumab + capivasertib
Sensitive: C3 – Early Trials
olaparib + durvalumab + capivasertib
Sensitive
:
C3
PIK3CA E545K
Gastric Cancer
PIK3CA E545K
Gastric Cancer
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
PIK3CA E545K
Ovarian Cancer
PIK3CA E545K
Ovarian Cancer
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
PIK3CA E545K
HER2 Negative Breast Cancer
PIK3CA E545K
HER2 Negative Breast Cancer
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
CYH33
Sensitive: C4 – Case Studies
CYH33
Sensitive
:
C4
PIK3CA E545K
Cervical Cancer
PIK3CA E545K
Cervical Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
GDC-0941
Sensitive: D – Preclinical
GDC-0941
Sensitive
:
D
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
PIK3CA E545K
HER2 Positive Breast Cancer
PIK3CA E545K
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
ado-trastuzumab emtansine
Sensitive: D – Preclinical
ado-trastuzumab emtansine
Sensitive
:
D
PIK3CA E545K
Breast Cancer
PIK3CA E545K
Breast Cancer
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
trastuzumab + lapatinib
Resistant: D – Preclinical
trastuzumab + lapatinib
Resistant
:
D
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
PIK3CA E545K
Thyroid Gland Papillary Carcinoma
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
MK-2206
Sensitive: D – Preclinical
MK-2206
Sensitive
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
RTB101
Sensitive: D – Preclinical
RTB101
Sensitive
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
BMS-722782
Resistant: D – Preclinical
BMS-722782
Resistant
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
trametinib
Resistant: D – Preclinical
trametinib
Resistant
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
GDC-0941
Resistant: D – Preclinical
GDC-0941
Resistant
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
rigosertib
Sensitive: D – Preclinical
rigosertib
Sensitive
:
D
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
PIK3CA E545K
Squamous Cell Carcinoma of Head and Neck
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
GDC-0032
Sensitive: D – Preclinical
GDC-0032
Sensitive
:
D
PIK3CA E545K
Melanoma
PIK3CA E545K
Melanoma
vemurafenib
Resistant: D – Preclinical
vemurafenib
Resistant
:
D
vemurafenib
Resistant: D – Preclinical
vemurafenib
Resistant
:
D
PIK3CA E545K
Hepatocellular Cancer
PIK3CA E545K
Hepatocellular Cancer
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
alpelisib
Sensitive: D – Preclinical
alpelisib
Sensitive
:
D
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
abemaciclib + RLY-2608
Sensitive: D – Preclinical
abemaciclib + RLY-2608
Sensitive
:
D
abemaciclib + RLY-2608
Sensitive: D – Preclinical
abemaciclib + RLY-2608
Sensitive
:
D
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
palbociclib + RLY-2608
Sensitive: D – Preclinical
palbociclib + RLY-2608
Sensitive
:
D
palbociclib + RLY-2608
Sensitive: D – Preclinical
palbociclib + RLY-2608
Sensitive
:
D
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
PIK3CA E545K
Hormone Receptor Positive Breast Cancer
RLY-2608
Resistant: D – Preclinical
RLY-2608
Resistant
:
D
RLY-2608
Resistant: D – Preclinical
RLY-2608
Resistant
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login